Table 2

NICE decisions and age

Year	Appraisal	Decision	Age restriction
2010	Rheumatoid arthritis—certolizumab	Yes	No
	Soft tissue sarcoma—trabectedin	Yes	No
	Hearing impairment cochlear implants	Yes—unilateral Yes—bilateral	No Children and adults with further disability
2009	Abdominal aortic aneurysm—endovascular stent grafts	Yes—unruptured	No
	Influenza—zanamivir, amantadine and oseltamivir (review)	Yes—at risk	Relaxed at risk criteria >65 years
	Renal cell carcinoma—sunitinib	Yes	No
	Venous thromboembolism—rivaroxaban	Yes	No
	Head and neck cancer (squamous cell cancer)—cetuximab	No	NA
	Multiple myeloma—lenalidomide	Yes	No
	Hepatitis B—tenofovir disoproxil fumarate	Yes	No
	Leukaemia (chronic lymphocytic, first line)—rituximab	Yes	No
	Colorectal cancer (first line)—cetuximab	Yes if operable	No
	Eczema (chronic)—alitretinoin	Yes if severe	No
	Renal cell carcinoma—bevacizumab, sorafenib and temsirolimus	No	NA
	Gastrointestinal stromal tumours—sunitinib	Yes	No
	Lung cancer (non-small cell, first line treatment)—pemetrexed	Yes	No
	Psoriasis-ustekinumab	Yes if severe	No
	Acute coronary syndrome—prasugrel	No except emergencies and DM	NA
	Cervical cancer (recurrent)—tapotecan	No except patient naive	NA
	Lung cancer (small cell)—tapotecan	Yes if CAV (cyclophosphamide, doxorubicin and vincristine) contraindicated	No
2008	Mesothelioma—pemtrexed disodium	Yes (if WHO performance status 0 or 1)	No
	Psoriasis—infliximab	Yes if severe	No
	Lymphoma (follicular non-Hodgkin's)—rituximab	Yes	No
	Structural imaging in first episode psychosis	No	NA
	Asthma (in adults) corticosteroids	Yes	>12 years
	Sleep apnoea—continuous positive airway pressure	Yes if moderate or worse	No
	Rheumatoid arthritis (refractory)—abatacept	No	NA
	Ulcerative colitis (subacute manifestations)—infliximab	No	NA
	Anaemia (cancer treatment induced)—erythropoietin (alpha and beta) and darbepoetin	No except non-transfusable and some cases of ovarian cancer	NA
	Ankylosing spondylitis—adalimumab, etanercept and infliximab	Yes if severe	No
	Head and neck cancer—cetuximab	No	NA
	Lung cancer (non-small cell)—bevacizumab (terminated appraisal)
	Psoriasis-adalimumab	Yes if severe	No
	Coronary artery disease—drug-eluting stents	No except small/long lesions	No
	Diabetes—insulin pump therapy	Yes under 12s	Child–adult distinction
	Hepatitis B—entecavir	Yes	No
	Hepatitis B—telbivudine	No	NA
	Macular degeneration (age-related)—ranibizumab and pegaptanib	Yes ranibizumab No pegaptanib	No
	Pregnancy (rhesus negative women)—routine anti-D	Yes	No
	Venous thromboembolism—dabigatran	Yes	No
	Osteoporosis—primary prevention	Yes with restrictions	Yes
	Osteoporosis—secondary prevention including strontium ranelate	Yes with restrictions	Yes
	Pain (chronic neuropathic or ischaemic)—spinal cord stimulation	Yes—severe	No
	Lung cancer (non-small cell)—erlotinib	Yes	No
	Organ preservation (renal)—machine perfusion and static storage	Yes	No
	Hyperuricaemia—febuxostat	No—unless allopurinol not possible	NA
	Ulcerative colitis (acute exacerbations)—infliximab	Yes—if ciclosporin inappropriate	No